[EN] CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE MIMÉTIQUES DU CD4 EMPÊCHANT LA PÉNÉTRATION DU VIH-1 ET LEURS MÉTHODES D'UTILISATION
申请人:DANA FARBER CANCER INST INC
公开号:WO2013090696A1
公开(公告)日:2013-06-20
Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gpl20, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD- 556.
CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US20140350113A1
公开(公告)日:2014-11-27
Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.
Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors
作者:Judith M. LaLonde、Young Do Kwon、David M. Jones、Alexander W. Sun、Joel R. Courter、Takahiro Soeta、Toyoharu Kobayashi、Amy M. Princiotto、Xueling Wu、Arne Schön、Ernesto Freire、Peter D. Kwong、John R. Mascola、Joseph Sodroski、Navid Madani、Amos B. Smith
DOI:10.1021/jm300265j
日期:2012.5.10
neutralization breadth. Herein, we report the design, synthesis, characterization, and X-ray structures of gp120 in complex with small molecules that simultaneously engage both binding hotspots. The compounds specifically inhibit viral infection of 42 tier 2 clades B and C viruses and are shown to be antagonists of entry into CD4-negative cells. Dual hotspot design thus provides both a means to enhance neutralization